



Ronald

45 | Male

Clinical Presentation


- Presents to PCP with increased moderate fatigue and malaise
- No current medications
- No significant past medical history or family medical history
- BMI 30
- BP 125/70



A pragmatic risk stratification approach is important to identify diabetic patients at risk of advanced fibrosis in a cost-effective fashion. I recommend using LIVERFAST as a screening blood test by a primary care provider [PCP].

Dr Imtiaz Alam

Clinical Associate Professor of Medicine
Texas A&M University



Before LIVERFAST™

Laboratory Results

- Fasting blood glucose: 215 mg/dl
- HbA1c: 9%
- Triglycerides: 125 mg/dl
- HDL: 60 mg/dl
- LDL: 100 mg/dl
- AST: 19 IU/L

Clinical Assessment

- Newly diagnosed Diabetes Mellitus
- Does Ronald meet the criteria of Metabolic Syndrome

What to do next?

- Treat for Diabetes Mellitus
- Risk management of metabolic syndrome
- Order LIVERFAST™

"There should be a high index of suspicion for NAFLD and NASH in patients with type 2 diabetes" (Chalassani N et al. Hepatology 2018. AASLD CPG)

"In patients with type 2 diabetes, the presence of NAFLD should be looked for irrespective of liver enzyme levels, since type 2 diabetes patients are at high risk of disease progression" (Chalassani N et al. Hepatology 2018. AASLD CPG)

LIVERFAST™ Results

Fibrosis

0.27
F0
No Fibrosis

Activity

0.41
A1
Mild Activity

Steatosis


0.48
S1
Mild Steatosis

After LIVERFAST™

Patient stratified as low risk of NASH or advanced fibrosis. Monitor for new risk factors.

"To monitor disease severity in 'Low risk' patients (indicative of no/mild fibrosis) with NAFLD, a follow up every 2 years is indicated using Liver enzymes and fibrosis biomarkers" (EASL-EASD-EASO. J Hepatol 2016 CPG)

- 1 Clinician orders **LIVERFAST™** for the patient
LIVERFAST Proprietary CPT Code 0166U
- 2 The patient has a **simple fasting blood test** of the 10 biomarkers
- 3 The lab provides **results** of the 10 biomarkers
- 4 The 10 biomarker results are input into Fibronostics **web portal**
- 5 Fibronostics' AI technology generates **LIVERFAST™** results immediately



LIVERFAST™

SAMPLE RESULT SHEET

Test id: 45843
Reference no: GLJ021031108907

PATIENT NAME:
RONALD

PHYSICIAN NAME:

DATE OF BIRTH: April 10, 1973

GENDER: MALE

HEIGHT: 5 ft 9 inch


WEIGHT: 203lb

BMI: 30

DATE TEST TAKEN: April 7, 2021

TEST SCORES


0.27



Fibrosis

0.27
Stage F0
No Fibrosis


0.41



Activity

0.41
Grade A1
Mild Activity

0.48



Steatosis

0.48
Grade S1
Mild Steatosis

INTERPRETATION

The result as per the SAF (Steatosis Activity Fibrosis) histological score is estimated at S1-A1-F0. This score indicates you have no fibrosis, mild activity, and mild steatosis.



BIOMARKER RESULTS

AGE: 48 years old GENDER: MALE BODY MASS INDEX: 30

Sample Date: November 5, 2020

Result	Unit	Result	Unit
alpha-2-Macroglobulin	205 mg/dL	ALT	59 IU/L
Haptoglobin	80 mg/dL	AST	45 IU/L
Apolipoprotein A1	152 mg/dL	Fasting Glucose	96 mg/dL
Total Bilirubin	0.3 mg/dL	Total Cholesterol	159 mg/dL
GGT	84 IU/L	Triglycerides	73 mg/dL

CLIA# 1002190357
This report is computer generated. No signature required.

- ✓ Algorithm calculation
- ✓ Results available real time
- ✓ Confidential, secure, and automatically sent to physician
- ✓ Support for interpretation available